SCHEMBL4126787

SCHEMBL4126787

C1=Cc2ccc(-c3ccccc3)cc2C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 1/20 0.39
ALOX5 P09917 1/20 0.38
PARP10 Q53GL7 1/20 0.38
PARP11 Q9NR21 1/20 0.38
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 2/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.37
KMT2A Q03164 2/20 0.37
NPC1 O15118 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
KDM1A O60341 4/20 0.37
KDM1B Q8NB78 1/20 0.37
ALDH1A1 P00352 3/20 0.36
TYRO3 Q06418 1/20 0.36
NTRK2 Q16620 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
HSP90AA1 P07900 2/20 0.35
HTT P42858 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5158791 0.84 TYRO3 (0.40) TDP2ALOX5PARP10PARP11KDM4E
SCHEMBL28861019 0.82 ESR1 (0.43) TDP2ALOX5MEN1KMT2AKDM1A
Biphenyl SCHEMBL27647964 0.81 CA1 (0.48) ALDH1A1HSP90AA1HTTFAAHPKM
SCHEMBL5064665 0.81 TDP2 (0.37) TDP2ALOX5PARP10PARP11KDM4E
SCHEMBL3420195 0.81 PARP10 (0.39) TDP2ALOX5PARP10PARP11KDM4E
SCHEMBL21126508 0.80 GSTP1 (0.49) ALOX5GAAMAPTMAOALMNA
Indene SCHEMBL27407473 0.79 CA1 (0.47) ALDH1A1HSP90AA1HTTFAAHPKM
Biphenyl SCHEMBL27261870 0.79 CA1 (0.47) ALDH1A1MAOAHSD17B10MAOBCA1
SCHEMBL6537108 0.78 HSD17B1 (0.37) TDP2MEN1KMT2AALDH1A1TYRO3
Biphenyl-4-Amine SCHEMBL9389022 0.76 CYP3A4 (0.54) KDM4EMEN1GAAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112105654-A Curable resin mixture, curable resin composition, and cured product thereof 日本化药株式会社 2020-12-18 CN disclosed
WO-2020031935-A1 CURABLE RESIN MIXTURE, CURABLE RESIN COMPOSITION, AND CURED PRODUCT 日本化薬株式会社 2020-02-13 WO disclosed
CN-102627522-B Synthesis method of indenofluorene derivatives, isotruxene and mono-substituted isotruxene derivatives UNIV EAST CHINA NORMAL 2013-11-27 CN disclosed
CN-102627522-A Synthesis method of indenofluorene derivatives, isotruxene and mono-substituted isotruxene derivatives UNIV EAST CHINA NORMAL 2012-08-08 CN disclosed
CN-1854134-B Piperazine compounds, their preparation method and pharmaceutical composition containing same SERVIER LAB 2010-04-21 CN disclosed
US-7612061-B2 Piperazine compounds LES LABORATOIRES SERVIER (FR) 2009-11-03 US disclosed
US-20090076030-A1 Piperazine compounds LES LABORATOIRES SERVIER (FR) 2009-03-19 US disclosed
US-20090075982-A1 Piperazine compounds LES LABORATOIRES SERVIER (FR) 2009-03-19 US disclosed
US-7465733-B2 Piperazine compounds LES LABORATOIRES SERVIER (FR) 2008-12-16 US disclosed
EP-1710240-B1 Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists SERVIER LAB (FR) 2007-12-05 EP disclosed
US-20060229318-A1 Piperazine compounds LES LABORATOIRES SERVIER (FR) 2006-10-12 US disclosed
WO-2006106241-A1 PIPERAZINE DERIVATIVES AND USE THEREOF AS SEROTONIN REUPTAKE INHIBITORS OR AS NEUROKININ ANTAGONISTS LES LABORATOIRES SERVIER (FR) 2006-10-12 WO disclosed
EP-1710240-A1 Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists Les Laboratoires Servier (FR) 2006-10-11 EP disclosed
EP-0969010-B1 Transition metal compound and catalyst containing the same for polymerization of olefins JAPAN POLYOLEFINS CO LTD (JP) 2004-09-22 EP disclosed
US-6352953-B1 TRANSITION METAL COMPLEX HAVING 5-MEMBERED RING FORMED BY TRANSITION METAL COMPOUND OF GROUP IVB, TWO CARBONS, METAL OF GROUP IIIA AND HYDROGEN JAPAN POLYOLEFINS CO., LTD. (JP) 2002-03-05 US disclosed
US-6150544-A Transition metal compound and catalyst containing the same for polymerization of olefins JAPAN POLYOLEFINS CO., LTD. (JP) 2000-11-21 US disclosed
EP-0969010-A2 Transition metal compound and catalyst containing the same for polymerization of olefins Japan Polyolefins Co., Ltd. (JP) 2000-01-05 EP disclosed
CN-1228072-A Process for preparing 2-aryl-substituted indenes MONTELL TECHNOLOGY COMPANY BV (NL) 1999-09-08 CN disclosed
EP-0505972-B1 Process for producing styrenic copolymer IDEMITSU KOSAN CO (JP) 1997-06-11 EP disclosed
EP-0505972-A2 Process for producing styrenic copolymer IDEMITSU KOSAN COMPANY LIMITED (JP) 1992-09-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075982-A1 Piperazine compounds HTR7, HTR5A, NPY5R TDP2 3974/4885ALOX5 370/4885PARP10 1052/4885
US-20090076030-A1 Piperazine compounds HTR7, HTR5A, NPY5R TDP2 3974/4885ALOX5 370/4885PARP10 1052/4885
US-20060229318-A1 Piperazine compounds HTR7, HTR5A, NPY5R TDP2 3974/4885ALOX5 370/4885PARP10 1052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.